Pharmacovigilance Report and Analysis 2009: Present Challenges and Future GoalsVisiongainApril 21, 2009 136 Pages - SKU: VSG2275013 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Summary
GBI Research, the leading
|
more...
|
$3,500.00
|
|
541711 Research and Development In Biotechnology: State Industry Market Evaluator
6/1/2012 | published by: BizMiner
This State Industry Market Evaluator reports on industry trends broken out for each US state. Each state sub-report is comprised of eight pages of data. Statistics are displayed for 2008-2009-2010 and 2011q2 for these measures:
|
more...
|
$699.00
|
|
World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)
3/1/2012 | published by: Kalorama Information
In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development,
|
more...
|
$3,795.00
|
|
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider, has released its latest research
|
more...
|
$3,500.00
|
|
Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs
4/20/2012 | published by: GBI Research
Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs Summary GBI Research, the leading business intelligence provider, has released its latest report, “Contract Manufacturing Organizations
|
more...
|
$3,500.00
|
|
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
4/30/2012 | published by: GBI Research
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation Summary GBI Research, the leading business intelligence provider, has released its latest research “Orphan Disease
|
more...
|
$3,500.00
|
|
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation
2/29/2012 | published by: GlobalData
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation Summary The report is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with
|
more...
|
$500.00
|
|
Global Biotechnology
4/4/2012 | published by: IBISWorld
Global Biotechnology Biotechnology is the application of science and technology to living organisms as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge and biotechnology products and
|
more...
|
$935.00
|
|
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
4/2/2012 | published by: GBI Research
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program Summary GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement
|
more...
|
$3,500.00
|
Related Markets
- Biotechnology
- General Biotechnology
- Genomics
- Pharmaceuticals
- General Pharmaceuticals
- Regulation & Policy
Regulation & Policy Reports
- Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs
- Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
